Article

Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimens

2023-01-04

Abstract excerpt

<h4>Purpose: </h4> Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare form of extranodal DLBCL. In this study, we aimed to determine the patterns of relapse and the optimal treatment strategy for PB-DLBCL in the rituximab era. Methods We retrospectively collected data from Chinese Southwest Oncology Group-affiliated institutes. Patients diagnosed with PB-DLBCL from 2008 to 2019 and treated with rit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b0971c51-7055-57f7-b452-0a99c717337f
DOI: 10.21203/rs.3.rs-2421391/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimensDOI 10.21203/rs.3.rs-2421391/v1Read

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.Semantic proximity Read

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read

[Characteristics and survival analysis of 60 cases of primary diffuse large B-cell lymphoma of the breast].Semantic proximity Read

[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma].Semantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.Semantic proximity Read

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read

[Impact of TP53 and MYD88 Mutations on Treatment Efficacy in Diffuse Large B-Cell Lymphoma].Semantic proximity Read

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.Semantic proximity Read

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03Semantic proximity Read